From Financial Modeling Prep: 2025-05-06 09:56:00

Vertex Pharmaceuticals reported first-quarter results below expectations, causing shares to drop over 5%. Adjusted earnings were $4.06 per share, missing estimates, while revenue of $2.77 billion fell short of forecasts. The company raised its 2025 revenue outlook to $11.85-$12 billion, reflecting confidence in product demand and new launches.

Vertex’s cystic fibrosis portfolio, led by TRIKAFTA/KAFTRIO, saw strong performance. U.S. revenue grew 9% to $1.66 billion, while international revenue declined 5% to $1.11 billion due to constraints in Russia. CEO highlighted business execution and focus on expanding pipeline beyond cystic fibrosis.



Read more at Financial Modeling Prep:: Vertex Drops 5% on Q1 Miss